Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Memantine hydrochloride is used for the palliative treatment of moderate to severe dementia of the Alzheimer's type (Alzheimer's disease). The current indication is based principally on 2 short-term (24 or 28 weeks) randomized, controlled clinical studies in adults (50-93 years of age) with a diagnosis of probable Alzheimer's disease that was moderate to severe. In both studies, patients treated with memantine hydrochloride received an initial dosage of 5 mg once daily, with weekly increases in increments of 5 mg daily until a dosage of 20 mg daily (10 mg twice daily) was reached. Patients enrolled in the 24-week study had received donepezil hydrochloride (a reversible acetylcholinesterase inhibitor) for at least 6 months (at a stable dosage for the preceding 3 months) and continued to receive donezepil hydrochloride in addition to either memantine hydrochloride or placebo during the study period. Various instruments were used to assess efficacy. In both studies, changes from baseline in cognitive performance were assessed using the Severe Impairment Battery (SIB) scale. Changes from baseline in overall daily function and overall clinical effects (including information from caregivers) were assessed using the modified Alzheimer's disease Cooperative Study Activities of Daily Living inventory (ADCS-ADL) and the Clinician's Interview Based Impression of Change (CIBIC plus), respectively. In both studies, patients receiving memantine hydrochloride experienced less deterioration in cognitive and daily function than patients receiving placebo. In the 24-week study, patients receiving memantine experienced less decline in CIBIC plus scores than patients receiving placebo; however, while improvements in CIBIC plus scores were observed in patients receiving memantine in the 28-week study, the difference from placebo (intent-to-treat analysis) was not statistically significant. In an unpublished 24-week open-label extension of the 28-week trial, improvement relative to the projected rate of continued decline in cognition, daily function, and overall clinical impression of change was observed in patients who were switched from placebo to memantine.
A third randomized, controlled clinical study of 12 weeks' duration was conducted in nursing home patients with severe dementia (Alzheimer's disease or vascular dementia). In patients randomized to receive memantine hydrochloride, therapy was initiated at a dosage of 5 mg once daily and increased to 10 mg once daily after one week. In this study, daily function was assessed using the care dependency subscale of the Behavioral Rating Scale for Geriatric Patients (BGP), and overall clinical effects were assessed using the Clinical Global Impression of Change scale (CGI-C); cognitive function was not evaluated. In a subset of patients diagnosed as having Alzheimer's disease, memantine hydrochloride was more effective than placebo, as assessed by changes from baseline in both the BGP and CGI-C scales.
Dosage and Administration
Memantine hydrochloride is administered orally (as a tablet or oral solution) without regard to meals. Memantine hydrochloride tablets and oral solution are equivalent on a mg-per-mg basis. The oral solution should be administered using the dosing device with oral syringe provided by the manufacturer, referring to the accompanying patient information for instructions. Memantine hydrochloride oral solution should not be mixed with any other liquid.
The recommended initial adult dosage of memantine hydrochloride is 5 mg once daily. The dosage of memantine hydrochloride shown to be effective in clinical trials and the recommended target dosage is 20 mg daily, given in 2 divided doses (10 mg twice daily). Dosage should be increased to the target dosage in increments of 5 mg daily at intervals of not less than 1 week. Following initiation of therapy at a dosage of 5 mg once daily, dosage should be increased to 10 mg daily (5 mg twice daily), with subsequent increases to 15 mg daily (5 mg and 10 mg as separate doses) and then to 20 mg daily (10 mg twice daily).
No dosage adjustment is needed in patients with mild to moderate renal impairment. However, in patients with severe renal impairment (i.e., creatinine clearance of 5-29 mL/minute), a target dosage of 5 mg twice daily is recommended. Creatinine clearance may be estimated using the following formulas:
Ccr male = [(140 - age) x weight (in kg)] / [72 x serum creatinine (in mg/dL)]Ccr female = 0.85 x Ccr male
Known hypersensitivity to memantine hydrochloride or any ingredient in the formulation.
Mematine has not been systematically evaluated in patients with a seizure disorder. In clinical studies, seizures occurred in 0.2% of patients receiving memantine and in 0.5% of patients receiving placebo.
Conditions that increase urinary pH (e.g., dietary changes [e.g., from a high-protein to a vegetarian diet], concomitant use of drugs that alkalinize urine [e.g., carbonic anhydrase inhibitors, sodium bicarbonate], renal tubular acidosis, severe urinary tract infections) may decrease elimination of memantine, resulting in increased plasma memantine concentrations; use with caution under such conditions.
Not known whether memantine is distributed into human milk. However, since many drugs are distributed into human milk, caution is advised if memantine is administered in nursing women.
Safety and efficacy not established in children.
Clinical studies have been conducted principally in older patients since dementia of the Alzheimer's type occurs mainly in an older patient population. Memantine pharmacokinetics were similar in elderly patients and younger adults.
Although pharmacokinetics have not been evaluated in patients with hepatic impairment, only a modest effect on clearance would be expected.
The area under the plasma concentration-time curve AUC was increased by 4, 60, or 115% in individuals with mild (creatinine clearance exceeding 50 but less than 80 mL/minute), moderate (creatinine clearance 30-49 mL/minute), or severe (creatinine clearance 5-29 mL/minute) renal impairment, respectively. Terminal elimination half-life was increased by 18, 41, or 95% in those with mild, moderate, or severe renal impairment, respectively. Dosage adjustment is recommended in patients with severe renal impairment, but not in those with mild or moderate renal impairment. (See Dosage and Administration: Special Populations.)
Common Adverse Effects
Adverse effects occurring in 2% or more of patients receiving memantine in clinical studies and more frequently than with placebo include dizziness (7%), confusion (6%), headache (6%), constipation (5%), cough (4%), hypertension (4%), back pain (3%), hallucination (3%), pain (3%), somnolence (3%), vomiting (3%), dyspnea (2%), and fatigue (2%).
Drugs Affecting Hepatic Microsomal Enzymes
Inhibitors or inducers of cytochrome P-450 (CYP) system; pharmacokinetic interaction unlikely.
Drugs Metabolized by Hepatic Microsomal Enzymes
Minimal inhibition of CYP isoenzymes 1A2, 2A6, 2C9, 2D6, 2E1, or 3A4 by memantine observed in vitro. No induction of CYP isoenzymes 1A2, 2C9, 2E1, or 3A4/5 observed in vitro at concentrations exceeding those associated with therapeutic efficacy. Pharmacokinetic interaction unlikely.
Because plasma protein binding of memantine is low (45%), a pharmacokinetic interaction with drugs that are highly protein bound (e.g., digoxin, warfarin) is unlikely.
Drugs Secreted by Renal Tubular Cationic Transport
Potential pharmacokinetic interaction (altered plasma concentrations of both drugs) when memantine is used with drugs secreted by the same renal cationic system (e.g., cimetidine, hydrochlorothiazide, metformin, nicotine, quinidine, ranitidine, triamterene). However, concomitant use of memantine with a fixed combination of hydrochlorothiazide and triamterene did not affect bioavailability of either memantine or triamterene, and maximum plasma concentrations and area under the plasma concentration-time curve (AUC) of hydrochlorothiazide decreased by only 20%. In addition, concomitant use of memantine with a fixed combination of glyburide and metformin hydrochloride did not affect the pharmacokinetics of memantine, metformin, or glyburide, and the hypoglycemic effects of the glyburide-metformin combination were not affected.
Potential decreased memantine clearance with resulting increases in adverse effects when the drug is used concomitantly with agents that increase urine pH (e.g., carbonic anhydrase inhibitors, sodium bicarbonate). Use with caution. Memantine clearance was decreased by approximately 80% at alkaline urine conditions (i.e., pH 8).
Concomitant use of memantine with the acetylcholinesterase inhibitor donepezil did not affect the pharmacokinetics of either drug or substantially alter acetylcholinesterase inhibition by donepezil. In a 24-week clinical study in patients with moderate to severe Alzheimer's disease, adverse effects observed with combination therapy with memantine and donepezil were similar to those observed with donepezil alone. In vitro and animal studies indicate that memantine does not affect the reversible inhibition of acetylcholinesterase produced by donepezil, galantamine, or tacrine.
N-Methyl-d-aspartate (NMDA) Antagonists
Concomitant use of memantine hydrochloride with other NMDA antagonists (e.g., amantadine, ketamine, dextromethorphan) has not been systematically evaluated. Use with caution.